Drugs / PanCytoVir™
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06025344 | Sep 2024 | — | TrippBio, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-12-12 | TrippBio, Inc. | Results TrippBio Presents at the World VaccineCongress West Coast 2023 Meeting trippbio.com ↗
All mice treated with PanCytoVir™ 100mg/kg survived. |
| 2023-12-04 | TrippBio, Inc. | Results TrippBio Publishes Data Comparing the invitro and in vivo Activity of PanCytoVir™versus Oseltamivir trippbio.com ↗
PanCytoVir™ was uniformly more potent than oseltamivir when tested in vitro across various cell lines. |
| 2023-08-29 | TrippBio, Inc. | Regulatory TrippBio Submits an Investigational New DrugApplication to the U.S. FDA for PanCytoVir™Treatment of Influenza trippbio.com ↗
This filing marks a significant milestone with the start of our second development program for the treatment of viral respiratory diseases. |
| 2023-08-03 | TrippBio, Inc. | Results TrippBio Announces Results of a Phase 2 Study of PanCytoVir™ in Patients with Mild-toModerate COVID-19 trippbio.com ↗
The median time to virologic clearance was significantly shorter for the PanCytoVir™ 1000 mg group than for placebo (7 days vs. 11 days, respectively; P<0.0001), and for the PanCytoVir™ 500 mg group versus placebo (9 days vs. 11 days, respectively; P<0.0001). |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PanCytoVir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06025344 ↗ |
| Route | Oral | “Single oral dose of 1000 mg (100 mg/mL) under fasted conditions” NCT06025344 ↗ |